HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

Omni Scents partners with Maxim Magazine on a fragrance collection; Oscar de la Renta launches fragrance Something Blue. More news in brief.

You may also be interested in...



Colgate Total Mouthwash Debut Makes “Complete Regimen”

Colgate-Palmolive rounds out its Colgate Total line with Pro-Shield mouthwash, bowing in the firm’s second quarter. Firm plans to support the launch with a “very robust” integrated marketing campaign featuring talk-show host Kelly Ripa.

Industry Vets Launch Boutique Fragrance Firm; Miss Universe Is First Client

The Miss Universe Organization is first to sign a licensing agreement with fragrance marketer and distributor Omni Scents, founded by former Parlux Fragrances CEO Neil Katz. Firm looks forward to launching three scents under the deal in August, noting that approximately 1 billion people in 190 countries tuned in to the 2012 Miss Universe pageant.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel